|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 |
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | SEC 1474 (9-02) | ||
| 1. Title of Derivative Security (Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) |
6. Date Exercisable and Expiration Date (Month/Day/Year) |
7. Title and Amount of Underlying Securities (Instr. 3 and 4) |
8. Price of Derivative Security (Instr. 5) |
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) |
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) |
11. Nature of Indirect Beneficial Ownership (Instr. 4) |
||||
| Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
| Applied Biosystems Group Employee Stock Options-Right to Buy | $ 25.575 | 11/14/2008 | M | 259,185 | (4) | 03/26/2011 | Applied Biosystems Group Common Stock | 259,185 | $ 0 | 10,815 | D | ||||
| Applied Biosystems Group Employee Stock Options-Right to Buy | $ 25 | 11/14/2008 | M | 40,000 | 08/16/2004 | 08/16/2011 | Applied Biosystems Group Common Stock | 40,000 | $ 0 | 0 | D | ||||
| Applied Biosystems Group Employee Stock Options-Right to Buy | $ 25 | 11/14/2008 | M | 40,000 | (5) | 08/16/2011 | Applied Biosystems Group Common Stock | 40,000 | $ 0 | 0 | D | ||||
| Applied Biosystems Group Employee Stock Options-Right to Buy | $ 20.85 | 11/14/2008 | M | 3,132 | (6) | 04/08/2012 | Applied Biosystems Group Common Stock | 3,132 | $ 0 | 0 | D | ||||
| Applied Biosystems Group Employee Stock Options-Right to Buy | $ 21.475 | 11/14/2008 | M | 262,500 | (7) | 06/02/2015 | Applied Biosystems Group Common Stock | 262,500 | $ 0 | 0 | D | ||||
| Reporting Owner Name / Address | Relationships | |||
| Director | 10% Owner | Officer | Other | |
| WHITE TONY L APPLIED BIOSYSTEMS INC. 301 MERRITT 7 NORWALK, CT 06851-1070 |
X | Chairman and CEO | ||
| /s/ Thomas P. Livingston, Attorney-in-Fact for Tony L. White | 11/18/2008 | |
| **Signature of Reporting Person | Date |
| * | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
| ** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| (1) | The price reported is the weighted average sale price in open market transactions at prices ranging from $30.00 to $29.25. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| (2) | Elizabeth Ann White Business Interests, LLLP, is a family limited partnership (the "FLP"). The reporting person's adult daughter is the sole general partner of the FLP, and the reporting person's wife and a grantor retained annuity trust established by the reporting person are currently the sole limited partners of the FLP. |
| (3) | The reporting person's wife is the sole trustee of the Tony Lee White 2007 Grantor Retained Annuity Trust. |
| (4) | These options originally became exercisable in four equal annual installments, commencing March 26, 2002 . Effective January 20, 2005, the vesting of all of these options was accelerated. However, shares received upon the exercise of accelerated options were subject to a restriction on transfer (covering sales, gifts, pledges, and any other method of disposition) that remained in effect for some of the shares until March 26, 2005. |
| (5) | These options originally became exercisable on or after the earlier of (a) August 16, 2006 or (b) two years after certain stock price targets were attained. The vesting of these options was accelerated effective June 2, 2005. However, shares received upon the exercise of accelerated options were subject to a restriction on transfer (covering sales, gifts, pledges, and any other method of disposition) that was to remain in effect until the earlier of the original vesting date of those options or termination of the reporting person's employment with the issuer. |
| (6) | These options originally became exercisable in four equal annual installments, commencing April 8, 2003. Effective January 20, 2005, the vesting of all of these options was accelerated. However, shares received upon the exercise of accelerated options were subject to a restriction on transfer (covering sales, gifts, pledges, and any other method of disposition) that remained in effect for some of the shares until April 8, 2006. |
| (7) | These options were fully vested and exercisable as of the grant date. However, shares acquired upon the exercise of these options were subject to a restriction on transfer (covering sales, gifts, pledges, and any other method of disposition). The transfer restriction was scheduled to lapse on 25% of the shares covered by the grant on each of the first four anniversaries of the grant date. Also, the transfer restriction would have lapsed in full upon termination of employment for any reason. However, all remaining restrictions were terminated on November 12, 2008. |